TICKERNERD
Menu
WHWKWHWKHealthcare · Biotechnology

WHWK Stock Forecast: Whitehawk Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 14 Oct 2026
$2.97
−1.66% on the day

The 9 Wall Street analysts covering Whitehawk Therapeutics, Inc. hold a median 12-month price target of $8 — +169.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 69 of 100 as at 14 Oct 2026 — in the upper half.

Market cap
$172.2M
Ticker Nerd rank
69 / 100
Median analyst target
$8.00
Analysts covering
9
Revenue$0.0
Operating income−$18.1M
Net income−$16.6M
Free cash flow−$14.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−12.9%
1M
−27.0%
YTD
+22.7%
1Y
+50.8%
From 52W high
−41.8%
From 52W low
+50.8%
$1.97
$5.10
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

WHWK stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Whitehawk Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Oct 2026
69 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
88
Revisions
83
Size
69
Accruals
66
Quality
64
Volatility
49
Growth
42
Issuance
34
Value
22

Momentum (88): The shares have been drifting up relative to others.

Value (22): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

WHWK stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on WHWK, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$4.00$6.00$8.00$10.00Jan 26Apr 26Jul 26Oct 26WHWKHigh $10.00Median $8.00Low $4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says9 analysts
6 Buy3 Hold0 Sell
Low $4.00Median $8.00High $10.00

The green dot is the last close — the median target sits +169.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
1 Oct 2026StifelInitiatesBuy$9.00
13 July 2026Leerink PartnersInitiatesOutperform$9.00
13 July 2026Leerink PartnersInitiatesOutperform—
25 June 2026B. Riley SecuritiesInitiatesBuy—
16 Apr 2026CitizensInitiatesMarket Outperform—
22 Dec 2025Jones TradingInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. WHWK appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

WHWK vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 14 Oct 2026, Whitehawk Therapeutics, Inc. returned +50.8% against +17.5% for the S&P 500, dividends included.

WHWK vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250Jan 26Apr 26Jul 26Oct 26WHWKS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

WHWK analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

Whitehawk Therapeutics, Inc. (WHWK) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
11.7×

Cheaper than 54% of US stocks

Price / sales
24.1×

Cheaper than 8% of US stocks

Price / book
0.9×

Cheaper than 72% of US stocks

EV / EBITDA
−0.0×

Cheaper than 62% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
−288.3%

Higher than 9% of US stocks

Net margin
89.4%

Higher than 99% of US stocks

Returns & dividend
Return on equity
−45.0%

Higher than 23% of US stocks

Return on assets
−28.7%

Higher than 15% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Whitehawk Therapeutics, Inc. (WHWK) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Whitehawk Therapeutics, Inc. has a market value of $172.2M and an enterprise value of $2.7M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$79.8M.

  • Diluted earnings per share, trailing twelve months: $−1.12.

  • Free cash flow in the twelve months to 30 June 2026: −$69.3M.

  • Shares outstanding: 57.0M.

  • Trailing P/E: 11.7×; forward P/E: −3.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Whitehawk Therapeutics, Inc. employs 32 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 14 Oct 2026

Data provided by Twelve Data

Peers

WHWK vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
WHWKWhitehawk Therapeutics, Inc.$172.2M
69
ORMPOramed Pharmaceuticals, Inc.$169.8M
74
NGENNervGen Pharma Corp.$168.3M
23
RNAAtrium Therapeutics, Inc.$171.1M
5
DTILPrecision BioSciences, Inc.$166.4M
67
STROSutro Biopharma, Inc.$172.4M
77
VRXAVERAXA Biotech AG$164.0M
23

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Whitehawk Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest WHWK news & analysis

Whitehawk Therapeutics Presents Real-World Analyses Supporting MUC16 as a Durable ADC Target in Ovarian Cancer at IGCS 2026

PRNewsWire · 1 Oct 2026positive

Whitehawk Therapeutics presented two real-world analyses at IGCS 2026 showing MUC16 expression remained high and stable following standard-of-care therapies in ovarian cancer, and that high MUC16 expression was associated with poor real-world overall survival in high-grade serous ovarian carcinoma. The findings support the scientific rationale for HWK-016, the company's next-generation MUC16-directed ADC currently in Phase 1 development.

Why it matters — These analyses provide clinical validation for MUC16 as a durable therapeutic target and support the scientific rationale behind Whitehawk's lead ADC candidate HWK-016, which is currently in Phase 1 development.

Whitehawk Therapeutics, Inc. (WHWK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha · 15 Sept 2026neutral

Whitehawk Therapeutics, Inc. presented at the Morgan Stanley 24th Annual Global Healthcare Conference, with a transcript of the presentation made available on Seeking Alpha.

Why it matters — A presentation at a major healthcare investor conference gives WHWK watchers insight into the company's current positioning and messaging to the investment community.

Whitehawk Therapeutics Presents Real-World Analyses Supporting PTK7 as a Durable ADC Target in EGFR Wild-Type Non-Small Cell Lung Cancer at WCLC 2026

PRNewsWire · 14 Sept 2026positive

Whitehawk Therapeutics presented two real-world analyses at WCLC 2026 that support PTK7 as a durable and clinically relevant ADC target in pretreated, EGFR wild-type non-small cell lung cancer. The analyses showed PTK7 expression remained stable following standard-of-care therapies, reinforcing the scientific rationale for the company's PTK7-directed ADC, HWK-007, currently in Phase 1 development.

Why it matters — The presentation bolsters the scientific case for Whitehawk's lead candidate, HWK-007, by indicating PTK7 remains a viable target in second- or later-line EGFR wild-type NSCLC.

Whitehawk Therapeutics Appoints Vijay Iyengar, MD, to Board of Directors

PRNewsWire · 10 Sept 2026positive

Whitehawk Therapeutics announced the appointment of Vijay Iyengar, MD, a former Incyte executive, to its Board of Directors, effective September 9, 2026. Iyengar brings extensive experience in oncology, corporate strategy, business development, and medical affairs.

Why it matters — A WHWK watcher would care because adding a biotech executive with deep oncology and business development expertise to the board could strengthen the company's strategic leadership as it advances its ADC cancer treatments.

Whitehawk Therapeutics to Participate in Upcoming Investor Conferences

PRNewsWire · 2 Sept 2026neutral

Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company, announced that its management will participate in investor meetings at the Cantor Global Healthcare Conference 2026 on September 9, 2026.

Why it matters — Investor conferences provide an opportunity for WHWK management to engage directly with the investment community and present their ADC-focused business.

FAQ

Frequently asked questions about WHWK stock

What is the WHWK stock price forecast for 2026-2027?

The 9 Wall Street analysts covering Whitehawk Therapeutics, Inc. have a median 12-month price target of $8, with estimates ranging from $4 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is WHWK stock a buy right now?

Of the 9 analysts covering Whitehawk Therapeutics, Inc., 6 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Whitehawk Therapeutics, Inc. 69 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank WHWK?

As at 14 Oct 2026, Whitehawk Therapeutics, Inc. ranks 69 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (88 of 100).

Will WHWK stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts implies +169.4% from the last close, and Ticker Nerd's factor model ranks Whitehawk Therapeutics, Inc. 69 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the WHWK stock forecast for 2030?

No analyst covering Whitehawk Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for WHWK are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $10 over the next 12 months.

How has WHWK stock performed over the past year?

Whitehawk Therapeutics, Inc. returned +50.8% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Whitehawk Therapeutics, Inc. do?

Whitehawk Therapeutics, Inc. is a clinical-stage oncology therapeutics company focused on developing antibody-drug conjugate (ADC) cancer treatments.

What is the latest news on WHWK?

The most recent item we track (PRNewsWire, 1 Oct 2026): "Whitehawk Therapeutics Presents Real-World Analyses Supporting MUC16 as a Durable ADC Target in Ovarian Cancer at IGCS 2026". Whitehawk Therapeutics presented two real-world analyses at IGCS 2026 showing MUC16 expression remained high and stable following standard-of-care therapies in ovarian cancer, and that high MUC16 expression was associated with poor real-world overall survival in high-grade serous ovarian carcinoma. The findings support the scientific rationale for HWK-016, the company's next-generation MUC16-directed ADC currently in Phase 1 development.

Company

About Whitehawk Therapeutics, Inc.

Whitehawk Therapeutics, Inc. is a clinical-stage oncology therapeutics company focused on developing antibody-drug conjugate (ADC) cancer treatments. Its current portfolio centers on three ADC assets designed to target clinically validated proteins across multiple tumor types, with emphasis on difficult-to-treat cancers. The company applies advanced technologies to tumor biology to support the development of more precise cancer therapies and to address limitations associated with earlier ADC approaches. Whitehawk Therapeutics works in the biotechnology sector and serves the broader oncology market through its research and development programs aimed at genetically and biologically defined cancers. Headquartered in Morristown, New Jersey, Whitehawk Therapeutics is positioned as a specialized drug development company centered on targeted cancer treatment innovation.

CEO Dr. David J. Lennon Ph.D. · 32 employees · United States · https://ir.whitehawktx.com